Ultragenyx Pharmaceutical, Inc. (RARE) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1162120,
    "name": "Ultragenyx Pharmaceutical, Inc.",
    "stock_name": "Ultragenyx Pharmaceutical, Inc.",
    "full_name": "Ultragenyx Pharmaceutical, Inc.",
    "name_url": "stocks-analysis/ultragenyx-pharmaceutical-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "36.54",
    "chg": 3.07,
    "chgp": "9.17%",
    "dir": 1,
    "prev_price": "33.47",
    "mcapval": "3,036.67",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US90400D1081",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "2.49 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/ultragenyx-pharmaceutical-inc-1162120-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Ultragenyx Pharmaceutical Hits Day High with Strong 8.12% Intraday Surge",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ultragenyx-pharmaceutical-hits-day-high-with-strong-812-intraday-surge-3585883",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/UltragenyxPharm_priceRelatedfactors_3585883.png",
        "date": "2025-10-01 16:15:06",
        "description": "Ultragenyx Pharmaceutical, Inc. saw a notable stock increase on September 30, 2025, reaching an intraday high. Despite recent gains, the company has faced a significant one-year decline. Positive quarterly results and strong institutional backing contrast with ongoing risks, including negative EBITDA and a high debt-to-equity ratio."
      },
      {
        "title": "Ultragenyx Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/ultragenyx-pharmaceuticals-technical-trend-shifts-from-bearish-to-mildly-bearish-amid-stock-price-increase-3586485",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/UltragenyxPharm_technicaldot_3586485.png",
        "date": "2025-09-30 16:12:15",
        "description": "Ultragenyx Pharmaceutical, Inc. has recently revised its evaluation amid challenging market conditions. The stock price has increased from the previous close, but the company has experienced significant declines over the past year and five years, contrasting sharply with broader market performance. Technical indicators show mixed signals."
      },
      {
        "title": "Is Ultragenyx Pharmaceutical, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ultragenyx-pharmaceutical-inc-technically-bullish-or-bearish-3578308",
        "imagepath": "",
        "date": "2025-09-29 11:17:45",
        "description": "As of 26 September 2025, the technical trend for Ultragenyx Pharmaceutical, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD is mildly bullish on the weekly timeframe but bearish on the monthly, while the RSI shows bullish momentum weekly but no signal monthly. Bollinger Bands and moving averages indicate a mildly bearish trend on the daily and weekly timeframes. Additionally, KST and Dow Theory are both bearish on the monthly timeframe. \n\nIn terms of performance, Ultragenyx has underperformed against the S&P 500 across multiple periods, with a year-to-date return of -30.88% compared to the S&P's 12.96%, and a one-year return of -47.34% versus 15.64% for the index...."
      },
      {
        "title": "Is Ultragenyx Pharmaceutical, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ultragenyx-pharmaceutical-inc-technically-bullish-or-bearish-3576736",
        "imagepath": "",
        "date": "2025-09-28 11:11:43",
        "description": "As of 26 September 2025, the technical trend for Ultragenyx Pharmaceutical, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD shows a mildly bullish signal on the weekly timeframe but is bearish on the monthly. The RSI indicates bullish momentum weekly, but there is no signal on the monthly. Bollinger Bands and moving averages are both mildly bearish on the daily and weekly timeframes. Additionally, Dow Theory and KST are bearish on the monthly, contributing to the overall bearish sentiment.\n\nIn terms of performance, Ultragenyx has underperformed the S&P 500 across multiple periods, with a year-to-date return of -30.88% compared to the S&P 500's 12.96%, and a one-year return of -47.34% versus 15.64% for the index...."
      },
      {
        "title": "Is Ultragenyx Pharmaceutical, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ultragenyx-pharmaceutical-inc-technically-bullish-or-bearish-3546673",
        "imagepath": "",
        "date": "2025-09-20 19:38:12",
        "description": "As of 2 September 2025, the technical trend for Ultragenyx Pharmaceutical, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages and the weekly indicators such as KST and Dow Theory, both indicating bearish conditions. The MACD shows a mildly bullish signal on the weekly timeframe but remains bearish on the monthly. The Bollinger Bands are bearish on both weekly and monthly timeframes. \n\nIn terms of performance, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -30.81% versus the S&P 500's 12.22%, and a one-year return of -49.55% compared to the S&P 500's 17.14%...."
      },
      {
        "title": "Is Ultragenyx Pharmaceutical, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-ultragenyx-pharmaceutical-inc-overvalued-or-undervalued-3543195",
        "imagepath": "",
        "date": "2025-09-20 18:13:14",
        "description": "As of 20 February 2018, the valuation grade for Ultragenyx Pharmaceutical, Inc. moved from does not qualify to risky, indicating increased concerns regarding its financial health. The company appears to be overvalued, given its high Price to Book Value of 24.36 and negative EV to EBITDA of -8.10, alongside a troubling ROE of -377.52%. In comparison to its peers, Madrigal Pharmaceuticals has a significantly worse P/E ratio of -35.88, while Corcept Therapeutics is categorized as very expensive with a P/E of 60.03, highlighting the relative valuation challenges Ultragenyx faces.\n\nThe company's stock has underperformed against the S&P 500 across multiple periods, with a staggering YTD return of -30.81% compared to the index's 12.22%. This trend of underperformance reinforces the notion that Ultragenyx is currently overvalued in the market...."
      }
    ],
    "total": 11,
    "sid": "1162120",
    "stock_news_url": "https://www.marketsmojo.com/news/ultragenyx-pharmaceutical-inc-1162120"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Ultragenyx Pharmaceutical Hits Day High with Strong 8.12% Intraday Surge

2025-10-01 16:15:06

Ultragenyx Pharmaceutical, Inc. saw a notable stock increase on September 30, 2025, reaching an intraday high. Despite recent gains, the company has faced a significant one-year decline. Positive quarterly results and strong institutional backing contrast with ongoing risks, including negative EBITDA and a high debt-to-equity ratio.

Ultragenyx Pharmaceutical Experiences Revision in Stock Evaluation Amid Market Dynamics

2025-09-30 16:12:15

Ultragenyx Pharmaceutical, Inc. has recently revised its evaluation amid challenging market conditions. The stock price has increased from the previous close, but the company has experienced significant declines over the past year and five years, contrasting sharply with broader market performance. Technical indicators show mixed signals.

Is Ultragenyx Pharmaceutical, Inc. technically bullish or bearish?

2025-09-29 11:17:45

As of 26 September 2025, the technical trend for Ultragenyx Pharmaceutical, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD is mildly bullish on the weekly timeframe but bearish on the monthly, while the RSI shows bullish momentum weekly but no signal monthly. Bollinger Bands and moving averages indicate a mildly bearish trend on the daily and weekly timeframes. Additionally, KST and Dow Theory are both bearish on the monthly timeframe. In terms of performance, Ultragenyx has underperformed against the S&P 500 across multiple periods, with a year-to-date return of -30.88% compared to the S&P's 12.96%, and a one-year return of -47.34% versus 15.64% for the index....

Is Ultragenyx Pharmaceutical, Inc. technically bullish or bearish?

2025-09-28 11:11:43

As of 26 September 2025, the technical trend for Ultragenyx Pharmaceutical, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD shows a mildly bullish signal on the weekly timeframe but is bearish on the monthly. The RSI indicates bullish momentum weekly, but there is no signal on the monthly. Bollinger Bands and moving averages are both mildly bearish on the daily and weekly timeframes. Additionally, Dow Theory and KST are bearish on the monthly, contributing to the overall bearish sentiment. In terms of performance, Ultragenyx has underperformed the S&P 500 across multiple periods, with a year-to-date return of -30.88% compared to the S&P 500's 12.96%, and a one-year return of -47.34% versus 15.64% for the index....

Is Ultragenyx Pharmaceutical, Inc. technically bullish or bearish?

2025-09-20 19:38:12

As of 2 September 2025, the technical trend for Ultragenyx Pharmaceutical, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages and the weekly indicators such as KST and Dow Theory, both indicating bearish conditions. The MACD shows a mildly bullish signal on the weekly timeframe but remains bearish on the monthly. The Bollinger Bands are bearish on both weekly and monthly timeframes. In terms of performance, the stock has underperformed significantly compared to the S&P 500 across multiple periods, with a year-to-date return of -30.81% versus the S&P 500's 12.22%, and a one-year return of -49.55% compared to the S&P 500's 17.14%....

Is Ultragenyx Pharmaceutical, Inc. overvalued or undervalued?

2025-09-20 18:13:14

As of 20 February 2018, the valuation grade for Ultragenyx Pharmaceutical, Inc. moved from does not qualify to risky, indicating increased concerns regarding its financial health. The company appears to be overvalued, given its high Price to Book Value of 24.36 and negative EV to EBITDA of -8.10, alongside a troubling ROE of -377.52%. In comparison to its peers, Madrigal Pharmaceuticals has a significantly worse P/E ratio of -35.88, while Corcept Therapeutics is categorized as very expensive with a P/E of 60.03, highlighting the relative valuation challenges Ultragenyx faces. The company's stock has underperformed against the S&P 500 across multiple periods, with a staggering YTD return of -30.81% compared to the index's 12.22%. This trend of underperformance reinforces the notion that Ultragenyx is currently overvalued in the market....

View All News